MedPath

Analysis of associations between high density lipoprotein structure and cholesterol efflux capacity in dyslipidemic patients treated with pitavastati

Not Applicable
Conditions
Hypercholesterolemia
Registration Number
JPRN-UMIN000014352
Lead Sponsor
Chu-NET
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Patients with contraindications to Livalo (2)Patients under treatment of anti-hyperlipidemic drugs (previous treatment of statin within 3 months, probucol within 6 months, or other anti-hyperlipidemic drugs within 1 month) (3)Previous treatments of hypertension excluding ARB, ACE inhibitor, and Ca blocker within 1 month (4)Patients with CK over upper limit of normal levels (5)Patients with AST and ALT over upper limit of normal levels (6)Smokers (7)Patients who cannot stop drugs prohibited for concomitant (8)Obese patients with BMI at least 30 kg/m2 (9)Patients with Nephrotic syndrome or diabetes mellitus (10)Patients with fasting plasma glucose at least 126 mg/dL or casual plasma glucose at least 200 mg/dL (11)Patients with 2 hours plasma glucose after 75g glucose load at least 200 mg/dL (12)Patients with HbA1c at least 6.5% (13)Patients with homozygous familial hypercholesterolemia (14)Patients under 20 years old (15)Patients judged to be inappropriate for this study by the investigators.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The association between cholesterol efflux capacity by HDL cholesterol and distribution of HDL subfractions and HDL proteins.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath